|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/17/19 Evolutionary Genomics, Inc. 10-Q 9/30/19 52:2.4M Edgar Filing LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 355K
2: EX-31.1 Certifications HTML 20K
3: EX-31.1 Certifications HTML 20K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 17K
46: R1 Document and Entity Information HTML 48K
31: R2 Condensed and Consolidated Balance Sheets HTML 91K
15: R3 Condensed and Consolidated Balance Sheets HTML 41K
(Parenthetical)
41: R4 Condensed and Consolidated Statements of HTML 58K
Operations
45: R5 Condensed and Consolidated Statement of HTML 46K
Stockholders' Equity
30: R6 Condensed and Consolidated Statements of Cash HTML 63K
Flows
14: R7 Business Activity HTML 23K
40: R8 Summary of Significant Accounting Policies HTML 32K
47: R9 New Accounting Standards HTML 22K
18: R10 Fair Value Measurements HTML 39K
25: R11 Property and Equipment HTML 28K
52: R12 Intangible Assets HTML 27K
36: R13 Stockholders' Equity and Warrants HTML 43K
17: R14 Stock-Based Compensation HTML 60K
24: R15 Commitments and Contingencies HTML 23K
51: R16 Related Parties and Transactions HTML 19K
35: R17 Concentrations HTML 19K
19: R18 Liquidity and Going Concern HTML 23K
23: R19 Summary of Significant Accounting Policies HTML 73K
(Policies)
44: R20 Fair Value Measurements (Tables) HTML 35K
38: R21 Property and Equipment (Tables) HTML 27K
13: R22 Intangible Assets (Tables) HTML 25K
29: R23 Stockholders' Equity and Warrants (Tables) HTML 38K
43: R24 Stock-Based Compensation (Tables) HTML 59K
37: R25 Business Activity (Details) HTML 18K
11: R26 Summary of Significant Accounting Policies (Other) HTML 24K
(Details)
28: R27 Summary of Significant Accounting Policies HTML 21K
(Property and Equipment) (Details)
42: R28 Summary of Significant Accounting Policies HTML 20K
(Intangible Assets) (Details)
39: R29 Summary of Significant Accounting Policies (Net HTML 26K
Loss Per Common Share) (Details)
33: R30 Fair Value Measurements (Details) HTML 29K
48: R31 Property and Equipment (Details) HTML 36K
26: R32 Intangible Assets (Details) HTML 48K
20: R33 Stockholders' Equity and Warrants (Narrative) HTML 43K
(Details)
34: R34 Stockholders' Equity and Warrants (Summary of HTML 41K
Warrants Activity) (Details)
49: R35 Stock-Based Compensation (Narrative) (Details) HTML 32K
27: R36 Stock-Based Compensation (Summary of Stock Options HTML 57K
Activity) (Details)
21: R37 Commitments and Contingencies (Details) HTML 28K
32: R38 Related Parties and Transactions (Details) HTML 21K
50: R39 Liquidity and Going Concern (Details) HTML 42K
22: XML IDEA XML File -- Filing Summary XML 90K
16: EXCEL IDEA Workbook of Financial Reports XLSX 42K
5: EX-101.INS XBRL Instance -- fnam-20190930 XML 687K
7: EX-101.CAL XBRL Calculations -- fnam-20190930_cal XML 101K
8: EX-101.DEF XBRL Definitions -- fnam-20190930_def XML 223K
9: EX-101.LAB XBRL Labels -- fnam-20190930_lab XML 528K
10: EX-101.PRE XBRL Presentations -- fnam-20190930_pre XML 398K
6: EX-101.SCH XBRL Schema -- fnam-20190930 XSD 84K
12: ZIP XBRL Zipped Folder -- 0001553350-19-001065-xbrl Zip 66K
| Certification |
CERTIFICATIONS
I, Steve Warnecke, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Evolutionary Genomics, Inc.
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting, to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
| |
|
|
BY: | /s/ Steve Warnecke |
| |
| Chief Executive Officer |
| (principal executive officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 10/17/19 | None on these Dates | ||
| For Period end: | 9/30/19 | |||
| List all Filings | ||||